COMPARISON OF CHOP CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR SLOWLY RESPONDING PATIENTS WITH AGGRESSIVE NON-HODGKIN'S LYMPHOMA
L e o K V e r d o n c k , M.D.> Wim L J. v a n P u t t e n , M.Sc., A n t o n H a g e n b e e k , M.D., H a r r y C. S g h o u t e n , M.D., P i e t e r S o n n e v e l d , M.D., G u s t a a f W. v a n I m h o f f , M.D., H a n n e k e C. K lu in -N e le m a n s , M.D., J o h n M.M. R a e m a e k e rs , M.D., R ie n H .J. v a n O e r s , M.D., H a n s L. H a a k , M.D., R ik S c i-io ts, M.D., A d r i a a n W. D e k k e r , M.D., G i j s b e r t C. Abstract Background. High-dose chemoradiotherapy combined with autologous bone marrow transplantation can cure patients with disseminated, aggressive nonHodgkin's lymphoma in whom first-line chemotherapy has failed. In contrast, cure is rare with second-line che motherapy. It has been suggested that patients with slow responses to the initial phase of first-line chemotherapy are at high risk for relapse. Therefore, such patients are potential candidates for early bone marrow transplan tation.
Methods. To investigate whether patients with slow responses, defined as only a partial response after three courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), would benefit from early trans plantation, we conducted a prospective, randomized tri al. The early application of high-dose chemoradiothera py and autologous bone marrow transplantation was compared with the continuation of CHOP therapy for an other five courses. Patients with complete responses af ter three courses of CHOP (fast responses) and patients who responded partially but still had tumor-positive mar row continued with another five courses of CHOP. The C OMBINATION chemotherapy can cure about 45 perccnt of patients with disseminated intermediate-grade or high-grade non-Hodgkin's lymphoma.1 Several institutions have reported that aggressive regi mens of chemotherapy containing six to eight drugs gave better results than the CHOP regimen (which contains cyclophosphamide, doxorubicin, vincristine, and prednisone),2'7 but in two large, multicenter, ran- study end points were the response rate, overall surviv al, disease-free survival, and event-free survival.
Results. Of 286 patients who could be evaluated for the rapidity of their response after three courses of CHOP, 38 percent had fast responses, 47 percent had slow respons es, and 15 percent had no response. Among 106 patients with slow responses who had lymphoma-negative marrow, 69 patients (65 percent) were randomized. Seventy-four percent of the CHOP group and 68 percent of the transplan tation group had complete remissions (P-0.54). At four years the rates of overall, disease-free, and event-free sur vival were 85, 72, and 53 percent, respectively, in the CHOP group and 56, 60, and 41 percent in the transplan tation group (P>0.10). The disease-free survival in both groups did not differ significantly from that of nonrandom ized patients with fast responses (54 percent at four years).
Conclusions. The early application of high-dose, mar row-ablative chemoradiotherapy with autologous bone marrow transplantation does not improve the outcome in patients with aggressive non-Hodgkin's lymphoma that responds slowly to first-line CHOP chemotherapy. (N Engl J Med 1995;332:1045-51.) domized, phase 3 trials8,9 the more aggressive regimens were not found to be superior to CHOP, which is wide ly used as first-line chemotherapy for non-Hodgkin's lymphoma. However, CHOP fails to cure the disease when remissions are incomplete or unstable. Retreat ment of patients who have relapsed with second-line, so-called salvage chemotherapy is generally unsuccess ful.10 High-dose chemoradiotherapy with autologous bone marrow transplantation may, however, cure some of these patients if they have disease that responds to chemotherapy.1 (M a Early in the course of treatment, or even at diagno sis, it is important to identify patients who are unlikely to have complete remissions. These high-risk patients may benefit from high-dose chemoradiotherapy with bone marrow transplantation while their lymphomas can still respond to first-line chemotherapy. It has been suggested that patients in whom complete remission occurs rapidly with first-line chemotherapy -i.e., within three cycles of conventional chemotherapy -1046 THE NEW ENGLAND JOURNAL OF MEDICINE April 20, 1995 have a better chance of cure than patients who respond more slowly. 19, 20 In 1987 wc began assessing the efficacy of high-dose marrow-ablative therapy combined with autologous bone marrow transplantation in patients with dissemi nated, aggressive non-Hodgkin's lymphoma who have slow responses to chemotherapy. All patients were treated with CHOP, and their responses were evaluat ed after three courscs. Those with partial responses were considered to have slow responses, and those with complete responses after three courses of CHOP were considered to have fast responses. We report here the results of a multicenter study in which patients with slow responses and lymphoma-negative bone marrow were eligible for random assignment to either another five courses of CHOP (the standard regimen) or mar row-ablative chemoradiotherapy with autologous bone marrow transplantation.
M e t h o d s
Between January 1987 and April 1994, we enrolled 320 patients in the study. Patients from 15 to 60 years of age were eligible if they had measurable, biopsy-confirmed intermediate-grade or high-grade nonHodgkin's lymphoma (groups D through H, according to the classi fication system of the Working Formulation),21 including unelassiiiable intermediate-grade and high-grade lymphoma, and stage II, III, or IV disease according to the Ann Arbor classification. The B or T immunotype was determined in either snap-frozen or paraffinembedded tissue with mouse monoclonal antibodies against B-cell antigens CD20 and MB2 and T-cell antigens CD3 and CD45, Patients were determined to be ineligible if they had previous che motherapy or radiotherapy; a history of low-grade malignant lym phoma; group I or J high-grade cancer; prior cancer, except non-mel anoma skin cancer or cervical carcinoma stage I; a positive serologic test for the human immunodeficiency virus; involvement of the cen tral nervous system by lymphoma; or severe cardiac, pulmonary, neu rologic, or metabolic disease. Informed consent was obtained from all patients. The pathology slides for 88 percent of the patients under went central pathology review'. The protocol was approved by the in stitutional review board of each center.
Staging of the extenL of disease, performed before therapy, includ ed a history taking and physical examination; complete blood counts, including a search for abnormal lymphoid cells in the blood by mor phologic and immunologic studies using flow cytometry; tests of renal and liver function; determination of the erythrocyte sedimentation rate; measurement of serum albumin and scrum electrolytes; protein electrophoresis and immunoclcctrophoresis; measurement of serum lactate dehydrogenase (upper limit, 250 U per liter); chest radiogra phy; computed tomography of the abdomen and thorax; consultation with an ear, nose, and throat specialist; and bone marrow biopsy and aspiration from the iliac crest, including immunophenotyping by immunoperoxidase. As clinically indicated, lumbar puncture or liver bi opsy was performed.
Complete restaging of each patient's condition was performed af ter three courses of CHOP chemotherapy and after the completion of therapy. During follow-up, staging procedures were repeated in their entirety at least every six months for the first three years and thereafter as clinically indicated.
Of the 320 patients enrolled, 34 patients were not eligible for the following reasons: they did not meet the criteria for entry into the study (6 patients), they had localized disease (5 patients), they had been treated before registration (2 patients), they had severe concom itant disease (4 patients), or the diagnosis was not confirmed (17 pa tients). Thus, 286 patients were eligible for analysis.
Treatment Protocol
CHOP was administered every 21 days as follows: 750 mg of cyclo phosphamide per square meter of hody-surface area intravenously on day 1; 50 mg of doxorubicin per square meter intravenously on day 1; 1.4 mg of vincristine per square meter intravenously on day 1 (maxi mal dose, 2.0 mg); and 100 mg of prednisone orally on days 1 through 5. Dose reductions were made as previously described if there was hematologic toxicity"; however, the first course was given in full. If there w'as mild neurotoxicity (i.e., paresthesias or decreased tendon reflexes), the dose of vincristine was reduced to 50 percent, and if there was severe neurotoxicity (i.e., marked loss of motor function), the vincristine was omitted. All patients were to receive three courses of CHOP and were then to be evaluated for their response.
To assess the response to CHOP, all tests that had abnormal re sults on staging before therapy were repeated. Complete remission was defined as the disappearance of all clinical evidence (physical and radiographic) of disease. Lymph nodes less than I cm in diame ter on radiography were considered uninvolved. Patients with residu al abnormalities detected with computed tomography, especially pa tients with bulky disease (tumor ^1 0 cm) at diagnosis, were not considered to be in complete remission unless the abnormality had decreased in size by 90 percent or more or unless biopsy proved it to be uninvolvcd. Partial remission was defined as a reduction by at least 25 percent of the sum of the largest tumor diameters. Progres sive disease was defined as an increase of at least 25 percent in the size of the original tumor mass or as the development of new lesions. Patients w-ho did not meet any of the preceding definitions were clas sified as having no response.
When they had completed the evaluation after the third cycle of CHOP, patients with partial remissions and no bone marrow infiltra tion were asked about entering the trial. Those who agreed to do so were randomized. The patients randomly assigned to transplantation underwent bone marrow' collection as soon as complete marrow re population had occurred. They were given a fourth course of CHOP the day after the collection. They then received high-dose chemother apy, radiation, and infusion of autologous marrow'.
Patients randomly assigned to CHOP began their fourth course on schedule. Those who had complete remissions and those with partial responses but with marrow' involvement were treated with five addi tional courses of CH O P Patients who had no response or whose dis ease progressed were not studied further and were given other ther apy at the discretion of the investigators.
Bone marrow collection and cryopreservation were performed as soon as the marrow was repopulated after the third course of GHOP.V i At least 2X10H nucleated cells per kilogram of body weight were collected, Reference samples of cells were frozen in small am pules and thawed during the first week after freezing in order for the investigators to check the quality of cryopreservation (with myeloid and erythroid colony growth in vitro). The absence of marrow in volvement by the lymphoma was checked again at the time of the marrow collection by histologic and cytologic methods, None of the patients assigned to transplantation had detectable marrow involve ment at the time of the marrow collection.
So that there would be time after the collection to evaluate the quality of the marrow graft and prepare for transplantation, the pa tients randomly assigned to transplantation received a fourth course of CHOP immediately after the bone marrow collection. The condi tioning regimen lor transplantation was scheduled to be carried out w'ithin six weeks after the fourth course of CHOP,
The high-dose chemoradiotherapy administered before the reinfu sion of autologous marrow consisted of cyclophosphamide (60 mg per kilogram, infused on each of two consecutive days), followed two days later by total-body irradiation (800 cGy in one fraction). The autol ogous (unpurged) marrow graft was thawed rapidly and reinfused through a central venous catheter the day after the total-body irra diation.
Statistical Analysis
The study was designed on the assumption that for paLients in par tial remission after three courses of CHOP, two-year event-free surviv al would be improved from 35 percent with the continuation of CHOP to 70 percent with bone marrow transplantation, which would mean an improvement for patients with slow' responses so that their outcome would be equivalent to that of patients with fast responses.19 Therefore, a total of 60 patients had to be randomly assigned to the two treat ments lor the study to have a power of 80 percent to detect such a dilference with a one-sided test at a significance level of 0.05. It w'as ex pected that 25 percent of the patients would have partial remissions without marrow infiltration after three courses of CHOP. Thus, accord ing to estimates before the study began, about 240 patients had to be enrolled for the induction treatment with CHOP in order to meet the CHARACTERISTIC objective of GO randomized patients. Eventual ly, 286 eligible patients were enrolled, 106 of whom (37 percent) had partial remissions without marrow infiltration and 69 of whom (24 percent) were randomized.
No further patients were admitted to the study alter December 31, 1993. The data were analyzed in April 1994, with the last follow-up data available for all patients still alive, except two patients (not randomized) who were lost to follow-up after one year. The median duration of follow-up for the 181 pa tients still alive at the final update was three years (range, two months to seven years). Six ty-one patients had follow-up of more than four years.
Logistic-rcgrcssion analysis, univariate and multivariate, was used to test and determine the strength of the association between the probability of complete remission and prog nostic factors and to determine the difference between the treatment groups. In these anal yses, only complete remissions in patients treated according to the protocol were con sidered -i.e., complete remission after three courses of CHOP, after continuing treatment with CHOP, or after bone marrow transplan tation for patients in partial remission after the first three cycles ol CHOP. Patients whose complete remissions occurred only lat er, with second-line treatment, were classified as having no com plete remission.
The actu arial method of Kaplan and Meier was used to calculate probabilities of survival. Cox regression analysis was used for statisti cal tests and the analysis of prognostic fac tors. The following end points were analyzed: overall survival, with failure defined as death from any cause; disease-free survival, which was restricted to patients entering complete remission while being treated according to the protocol, with failure defined as relapse or death during a first complete remission; and event-free survival, with failure defined as no complete remission during treatment accord ing to the protocol, relapse after a complete remission, or death during a first complete re mission. Time was measured from the start of the first treatment with CHOP or, in the comparison of the randomized treatment groups, from the time of randomization. Disease-free survival was measured from the date of complete remission. From the esti mate of the relative death rate (R) in the transplantation (ABMT) group as compared with the CHOP group, obtained from the Cox model, the corresponding difference in overall survival (OS) between the two groups (OSABMT-OS(;HO,> ) was calculated by the for mula OSAI,MT = OS,\ în(,j,. In this formula, the overall survival after CHOP therapy was set at 70 percent. The 95 percent: confidence interval for this difference in survival was calculated by substituting ibr 11 the 95 percent confidence intervals of the estimated relative death rate.
The following variables were included in the analysis of prognostic factors: age, sex, histologic grade of cancer (i.e., intermediate vs. high), Ann Arbor stage, number of extranodal sites, bone marrow involvement, bulky disease, immunologic phenotype, serum concen tration of lactate dehydrogenase, and performance status (assessed according to the classification system of the World Health Organiza tion). For all the statistical tests, a significance level of 0.05 was used. All reported P values are two-sided and unadjusted.
Interim analyses with rules for stopping in the event of extreme differences in outcome favoring the transplantation group were planned and performed twice during the study. The statistical crite- rion for stopping the accrual of patients was an improvement in over all survival in the transplantation group that was statistically signif icant at the level of P<0.005. Because of this stringent criterion, no adaptation of the nominal significance levels at the final evaluation was required.
R e s u l t s
Response after Three Courses of CHOP Chemotherapy Table 1 shows the characteristics of all 286 eligible patients at diagnosis and the subgroups of patients ac cording to their responses after three courses of CHOP. Among the 286 patients, 110 (38 percent) had com-THE NEW ENGLAND JOURNAL OF MEDICINE April 20, 1995 plcte remissions after the first three courses of CHOP, 133 (47 percent) had partial remissions, and 43 (15 percent) had either no response or progression of dis ease (Table 2) . Of the 133 patients who had partial re sponses, 27 still had lymphoma in the bone marrow and were therefore ineligible for randomization. Thus, 106 patients qualified for randomization, and 69 of them ((55 percent) were randomized. Thirty-seven patients (35 percent) were not randomized for the fol lowing reasons: refusal by the patient (22 patients), psychological reasons (4), medical reasons (5), and ad ministrative errors (6) . Table 1 shows the clinical features of the patients randomly assigned to CHOP or bone marrow' trans plantation. The two groups were well balanced, espe cially with regard to the prognostic variables defined by the international index established by the International Non-Hodgkin's Lymphoma Prognostic Factors Proj ect.'^ At randomization, 35 patients were assigned to continue standard treatment with CHOP, and 34 pa tients were assigned to transplantation. Howevez*, eight patients assigned to the transplantation group did not proceed to that treatment; three declined the treat ment, and five had progressive disease. Of the patients assigned to CHOP who continued that treatment, sev en patients did not complete all eight courses because of progressive disease.
Response of the Randomized Patients
The conditioning regimen for transplantation was started a median of 27 days (range, 17 to 60) after the fourth course of CHOP. In fact, 26 of 28 patients start ed the conditioning regimen within 39 days after the fourth course of CHOP. The results were analyzed on an intention-to-treat basis. Twenty-six of the 35 pa tients (74 percent) randomly assigned to CHOP had complete remissions, as compared with 23 of the 34-patients (68 percent) randomly assigned to transplan tation (Table 2) . This difference was not significant (P = 0.54). The exclusion of the 15 patients who did not complete the treatment as planned could have biased the outcome, because 12 of these patients had early progressive disease. Analysis according to actual treat- ments did not change the results; among the 28 pa tients in the CHOP group who completed eight courses of CHOP, 26 reached complete remission, 6 relapsed, and only 1 died, whereas among the 26 patients in the transplantation group who underwent transplantation, 23 reached complete remission, 7 relapsed, and 9 died.
Survival of the Randomized Patients
The mean (±SE) estimated overall survival four years from randomization was 85±6 percent in the CHOP group and 56±10 percent in the transplanta tion group (Fig. 1) . Disease-free survival at four years was 72±10 percent in the CHOP group and 60±12 percent in the transplantation group. Event-free surviv al at four years was 53 ±9 percent in the CHOP group and 41 ±10 percent in the transplantation group (Fig.  2 ). There were no significant differences between the two treatment methods in overall survival (hazard ratio for transplantation vs. CHOP, 2.2; 95 percent confidence interval, 0.82 to 5.9; P = 0.12), disease-free survival (hazard ratio, 1.5; 95 percent confidence inter val, 0.49 to 4.3; P = 0.50), or eventfree survival (hazard ratio, 1.3; 95 percent confidence interval, 0.66 to 2.61; P = 0.43). Six patients in the CHOP group and seven patients in the transplantation group relapsed. Six patients assigned to the CHOP group died, all of lymphoma, where as 12 patients in the transplantation group died, 10 of lymphoma and 2 of treatment-related toxic effects.
Response of the Nonrandomized Patients
The 110 patients in complete re mission, the 27 patients with partial responses and marrow involvement, and the 37 nonrandomized patients with partial responses but no marrow involvement were all scheduled to continue with another five courses of CHOP (Table 2) . Among the 110 patients in com plete remission, 44 patients (40 percent) relapsed dur ing CHOP treatment or thereafter. Among the 27 pa tients with partial responses but with bone marrow involvement, 10 patients (37 percent) had complete re missions. The rate of' complete remission in these pa tients was significantly lower (P = 0.006) than that in the patients who had partial remissions but who had no marrow infiltration. Among the 37 nonrandomized pa tients with partial responses and no bone marrow in volvement, 23 (62 percent) had complete remissions during CHOP therapy. For these 37 patients, overall, disease-free, and event-free survival at four years was 55, 70, and 43 percent, respectively.
Survival of the Eligible Patients
Among all 286 study patients, actuarial overall sur vival at four years was 59 ±3 percent (Fig. 3) , and for the 192 patients with complete responses disease-free survival at four years was estimated to be 58±3 per cent. For the nonrandomized group of patients with last responses (those in complete remission after three courses of CHOP), disease-free survival at four years was 54-±5 percent. Table 2 shows the causes of death in the various treatment groups. Figure 4 shows that there was no significant difference in survival between patients in complete remission after three courses of CHOP (those with fast responses) and patients with partial (slow) responses. The outcome in patients with either no response or progressive disease was signifi cantly worse (P<0.001) than in patients who had com plete or partial remissions.
Analysis of Prognostic Factors
Multivariate analysis showed that for all eligible pa tients enrolled in the study, the following prognostic factors were predictive of overall survival: Ann Arbor stage (II vs. III vs. IV; P<0.001), histologic grade of cancer (intermediate vs. high; P = 0.01), serum concen tration of lactate dehydrogenase (<750 vs. ^750 U per liter; P<0.001), and performance status (0 or 1 vs. 2, 3, or 4; P<0.001). Other prognostic factors did not have additional predictive value. Except for the grade of can cer, these prognostic factors agree with those defined by the international index.23 Adjustment for these factors did not affect the nonsignificant differences between the randomized treatment groups.
D is c u s s io n
We assessed the value of early intervention with high-dose, marrow-ablative chemoradiotherapy and au tologous bone marrow transplantation in patients with disseminated, aggressive non-Hodgkin's lymphoma who had slow responses to standard CHOP chemotherapy. There were no significant differences in the rates of complete remission, estimated overall survival, diseasefree survival, and event-free survival between patients who received bone marrow transplantation and those who continued with the conventional therapy.
The number of patients randomized was only suffi cient to show the expected difference in outcome of 35 percent between the two treatment methods, The rela tive risk of death in the transplantation group as com pared with the CHOP group was 2.2 (95 perccnt con fidence interval, 0.8 to 5.9). This value corresponds to a difference in the probability of overall survival of -23 percent (95 percent confidence interval, +5 percent to -58 percent), if a 70 percent probability of long-term overall survival in the CHOP group is assumed. This result implies that a small benefit of transplantation cannot be excluded, but any substantial benefit is ex tremely unlikely. Considering the cost of bone marrow transplantation and the failure of this very intensive treatment to improve overall survival and disease-free survival, we conclude that the early use of transplanta tion in patients with slow responses is not useful. It re mains to be clarified whether autologous bone marrow transplantation may have a role among patients in the recently defined high-risk subgroup of the international index who have very poor survival after conventional first-line chemotherapy or among patients with a re sponse but with proved residual disease after first-line chemotherapy. When our study began, it was suggested that patients with aggressive non-Hodgkin's lymphoma1E ),2ii or other hematologic cancers24,25 who had complete responses rapidly might have a better probability of cure than those with slower responses to chemotherapy. A recent comprehensive review of several phase 2 studies sup ports this hypothesis.2* 1 The ability to stratify patients early in the course of disease as being at either high or low risk appears clinically important; high-risk patients may benefit from experimental approaches such as high-dose therapy with transplantation, whereas lowrisk patients should not receive unusually hazardous treatments. With its international index, the Interna tional Non-Hodgkin's Lymphoma Prognostic Factors Project has defined factors present at diagnosis that distinguish patients in groups with good, intermediate, or poor survival. 21 The value of these prognostic factors was confirmed in our study; application of the interna tional index to ail study patients gave probabilities of four-year overall survival comparable to those reported by the international index,23 ranging from 78 percent in the low-risk group to 24 percent in the high-risk group (data not shown).
Although 106 patients were eligible for random as signment to transplantation or to another five courses of CHOP, only 69 patients (65 percent) were actually randomized. Thus, 37 patients were not randomized, mainly because the patients declined randomization. There were no significant differences in rates of com plete remission or overall, disease-free, or event-free survival between patients who were randomly assigned to the two treatment groups, or among the two groups and the 37 nonrandomized patients who also received five more courses of CHOP. In fact, the estimated rates of disease-free and event-free survival at four years were 72 and 53 pcrcent, respectively, for the random ized CHOP group and 60 and 41 percent for the trans plantation group, as compared with 70 and 43 percent for the 37 nonrandomized patients. Procedure-related deaths occurred in 6 percent of the transplantation group; mortality was similar (5 pcrcent) in the nonran domized CHOP groups. Probably by chance, proce dure-related deaths did not occur in the randomized CHOP group. Furthermore, 54 percent of the nonran domized group of patients with fast responses (those in complete remission after three courses of CHOP) who continued with another five courses of CHOP were alive without disease at four years. Thus, those who re sponded slowly did as well as those who responded rap idly. Apparently, it was the fact that they had complete remissions that was predictive of outcome, rather than the time required to attain them. Although most phase 2 studies of the value of a rapid response reported that the speed with which patients achieved complete remis sions was an important prognostic factor, l9» 21,» 2(l two studies could not confirm this finding.21' This discrep ancy may be caused by the follow-up periods, which were relatively short in most of these studies.
We are aware of only two other studies in which high-dose therapy and autologous bone marrow trans plantation were compared with chemotherapy in patients with aggressive non-Hodgkin's lymphoma. In these studies transplantation was not used early, but was applied after the completion of conventional che motherapy. A multicenter Italian study27 compared high-dose chemotherapy and transplantation with sal vage chemotherapy in patients who were in partial remission after the completion of first-line chemothera py. The results suggested a better disease-free survival for the transplantation group. A multicenter French study2 1 1 compared intensive, but not mar row-ablative, chemotherapy and bone marrow transplantation with intensive sequential chemotherapy in patients who were in complete remission after first-line chemotherapy. This study found no difference in disease-free survival between the two treatments. Although both studies dif fer from this one on several points, their data suggest that high-dose therapy combined with bone marrow transplantation does not improve outcome in patients who are in either very good partial remission (with re sidual abnormalities of unknown importance) or com plete remission after chemotherapy.
We conclude that the early use of marrow-ablative chemoradiotherapy with autologous bone marrow trans plantation offers no significant benefit in patients with aggressive non-Hodgkin's lymphoma who have re sponded slowly to first-line cheinotherapy. Further more, the rapidity with which complete remission is achieved appears to have no prognostic importance.
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